Drug news: EyeGate Pharma EGP-437 Phase II results
EyeGate Pharma Announces That EGP-437 Improved Signs And Symptoms Of Dry Eye Syndrome In A Phase II Study
altham, MA – June 3, 2009 – Based on the top-level analysis of a Phase II study, EyeGate Pharma announces that EGP-437, a corticosteroid solution administered by a non-invasive ocular drug delivery system, improved signs and symptoms in patients with dry eye syndrome (DES)....
In the top-level analysis, investigators observed that EGP-437 significantly (p < 0.05) improved signs and symptoms of DES during the three-week environmental component, which included three CAE exposures and two doses. EGP-437 also improved signs and symptoms when studied as a treatment and preventative in conjunction with the CAE.